A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics is a research paper published in Neuro-Oncology (2022). On theSindex it has a DataRank of 0.663. It has been cited 82 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.663
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: P30-CA008748
National Institutes of Health
Grant: P30CA013696
National Institutes of Health
Grant: UG1CA189960
National Institutes of Health
Grant: P50CA221747
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 5P50CA221747-02
SPORE for Translational Approaches to Brain Cancer
National Institutes of Health
Grant: 3P30CA013696-21S1
CANCER CENTER CORE SUPPORT GRANT
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
Chimerix
Millenium
Pfizer
Novocure
Orbus Therapeutics
Genentech
Novartis
FWCI
9.13
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals